Rafael Pharmaceuticals Announces the Initiation of a Phase 1b/2 Clinical Trial of CPI-613® (devimistat) in Combination with Gemcitabine and Cisplatin in Patients with Biliary Tract Cancer

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Pat Purcell
Meeting Engagement

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Brenda Snow
Authentic Patient Voice

Joey Cohen
Medication Adherence